Biodexa Pharmaceuticals Plc
Business
Biodexa Pharmaceuticals Plc is a clinical-stage biopharmaceutical company developing therapies for diseases with unmet medical needs. It develops proprietary therapeutics including eRapa (a nanotechnology-enabled rapamycin formulation), tolimidone (a lyn kinase activator for type 1 diabetes), and MTX110 (a convection-enhanced delivery formulation of panobinostat for rare brain cancers). Its operations include clinical-stage assets supported by three drug delivery technology platforms (Q-Sphera, MidaSolve and MidaCore) focused on sustained delivery and nanoparticle/oligosaccharide technologies. The company conducts clinical development primarily in Europe and in international markets via clinical trials and licensing/distribution channels.
Summary from filing dated 2025-04-11
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-6.38M |
| Total assets | $18.18M |
| Total liabilities | $6.77M |
| Stockholders' equity | — |
| Operating cash flow | — |